Cost regulators for treatments used by the NHS in England and Wales have published three sets of final guidances giving routine access to new options for lung cancer, rheumatoid arthritis and hepatitis C, and one rejecting a new therapy for melanoma.
Read More
Cost regulators for the NHS in England and Wales are backing use of Merck, Sharp & Dohme’s hepatitis C therapy Zepatier, potentially giving patients with certain types of the condition ‘routine’ access to another treatment option.
Read More
European regulators have waved through Merck, Sharp & Dohme’s Zepatier bringing a new treatment option to patients with hepatitis C.
Read More
Six medicines, including two new combination therapies for chronic hepatitis C, are lining up for EU approval after having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
